1. Home
  2. VET vs SNDX Comparison

VET vs SNDX Comparison

Compare VET & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vermilion Energy Inc.

VET

Vermilion Energy Inc.

HOLD

Current Price

$13.94

Market Cap

1.5B

Sector

Energy

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$24.00

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VET
SNDX
Founded
1994
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.8B
IPO Year
2004
2014

Fundamental Metrics

Financial Performance
Metric
VET
SNDX
Price
$13.94
$24.00
Analyst Decision
Hold
Strong Buy
Analyst Count
1
12
Target Price
$15.00
$84.17
AVG Volume (30 Days)
2.5M
1.2M
Earning Date
03-04-2026
05-04-2026
Dividend Yield
2.65%
N/A
EPS Growth
N/A
11.56
EPS
N/A
N/A
Revenue
N/A
$172,352,000.00
Revenue This Year
$15.13
$112.05
Revenue Next Year
N/A
$51.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
627.84
52 Week Low
$5.14
$8.59
52 Week High
$14.70
$25.16

Technical Indicators

Market Signals
Indicator
VET
SNDX
Relative Strength Index (RSI) 76.67 64.15
Support Level $7.42 $19.46
Resistance Level N/A $25.16
Average True Range (ATR) 0.62 1.12
MACD 0.22 0.09
Stochastic Oscillator 77.31 67.57

Price Performance

Historical Comparison
VET
SNDX

About VET Vermilion Energy Inc.

Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, development, and optimization of producing properties in North America, Europe, and Australia. The majority of Vermilion's revenue is derived from the production and sale of petroleum and natural gas. In each market, the company relies on a host of drilling and well-completion techniques to keep production at attractive levels. Geographically, the company derives majority of its revenue from Canada.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: